Drug Profile


Alternative Names: Research programme: ulcerative colitis therapy - Dr Falk Pharma/Targacept; TC 2403-12; TC-2403; Ulcerative colitis therapy research programme - Targacept/Dr Falk Pharma

Latest Information Update: 13 Dec 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targacept
  • Developer Dr Falk Pharma; Targacept
  • Class Neuroprotectants; Nootropics; Pyridines; Small molecules; Solanaceous alkaloids
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 02 Dec 2004 A clinical study has been added to the adverse events section
  • 09 Jun 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Inflammatory Bowel Disorders pharmacodynamics section
  • 19 Mar 2003 Phase-II clinical trials in Ulcerative colitis in USA (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top